ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
ESMO 2026 Exhibitors
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
235 organizations exhibit at ESMO 2026 — 145 industry and service companies, 74 drug developers, 13 societies and non-profits and 3 cancer centres and hospitals. 59 of them also present on the scientific program, with 208 presentations between them. Most represented: MD Anderson Cancer Center, Institut Curie and City of Hope. As of Nov 2, 2026.
Tumour type
Top represented
Showing 1–30 of 235 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, TX | |
Comprehensive cancer treatment and research centre of the University of Texas in Houston, Texas. | Booth Exhibiting at Booth 8006 Poster Fri Oct 23 13:00–15:00 A phase 2 study of emiltatug ledadotin (Emi-Le) in patients with aggressive adenoid cystic carcinoma: EMBLEM-1 Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 AI-informed novel biomarker discovery for BRAF + EGFR + PD-1 therapies in MSS, BRAFV600E metastatic colorectal cancer (mCRC) Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Cisplatin or carboplatin? A quantitative umbrella review of meta-analyses in solid tumors to inform treatment choice Gynaecological cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Delineating the targetable transcriptome in cancers of unknown primary (CUP) for antibody-drug conjugates (ADC) Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Integrated analysis of tissue, plasma and PBMCs in triple negative inflammatory breast cancer patients by response to KEYNOTE-522 regimen Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Long-term results of ASP-1929 photoimmunotherapy (PIT) with pembrolizumab (PEM) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Phase 1/2 study of the novel werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Preclinical evaluation of CD70-directed antibody-radionuclide conjugate platform for the management of clear cell renal cell carcinoma Haematological malignanciesGenitourinary cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Talk Fri Oct 23 14:30–14:45 Abstract Fri Oct 23 14:32–14:37 702RO - Immune checkpoint blockade for patients with leptomeningeal metastases from non-small cell lung cancer Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Analysis of the safety, tolerability, and PK of EIK1005, a novel WRN inhibitor Gastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Evaluation of ctDNA minimal residual disease (MRD) testing to complement radiographic surveillance in patients (Pts) with colorectal cancer (CRC): Results from the MD Anderson (MDA) INTERCEPT program Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 First-in-human trial of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor, in MTAP-deficient advanced tumors Gastrointestinal cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 15:15–16:00 Goblet cell appendiceal adenocarcinoma is a distinct disease entity defined by LGR5/Wnt mediated oncogenesis driving an immune-excluded tumor microenvironment Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Prevalence, prognosis, and impact on tumor microenvironment (TME) of homozygous MTAP deletion (MTAP-del) in advanced solid tumors Gastrointestinal cancersLung & thoracic cancersGenitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Safety and activity of IAM1363, a CNS penetrant HER2 TKI in participants with HER2 altered advanced cancers Gastrointestinal cancersGynaecological cancersBreast cancerSarcoma, CNS, head & neck and rare cancersGenitourinary cancers Poster Fri Oct 23 15:15–16:00 Chair Fri Oct 23 16:15–17:45 Emerging therapeutic strategies in advanced prostate cancer Genitourinary cancers Abstract Fri Oct 23 16:47–16:52 Talk Fri Oct 23 17:15–17:35 New targets (ADCs, new biologies) Genitourinary cancers Satellite Fri Oct 23 18:45–19:10 Elacestrant in ESR1-mutant mBC: Establishing the Standard of Care Breast cancerBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:35–08:40 Abstract Sat Oct 24 08:45–09:00 Invited Discussant LBA73, 2719RO and 2700RO Lung & thoracic cancers Talk Sat Oct 24 09:10–09:30 Poster Sat Oct 24 12:00–12:45 A phase 2 study of neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): Final analysis Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 RNA-seq phasing spotlights secondary oncogenic mutations for clinical interpretation Biomarkers & precision oncology Satellite Sat Oct 24 13:05–13:25 KRAS G12C Biology: A Unique Oncogenic Driver With Dual Impact Lung & thoracic cancers Satellite Sat Oct 24 14:00–14:15 A new chapter? The evolving role of ADCs in mCRC Gastrointestinal cancers Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 15:05–15:15 Abstract Sat Oct 24 15:15–15:27 Chair Sat Oct 24 16:30–18:00 Updates on myeloid neoplasms with a focus on medical oncology practice Haematological malignancies Talk Sat Oct 24 17:10–17:30 Current treatment landscape of AML based on a comprehensive genomic assessment Haematological malignancies Abstract Sun Oct 25 08:30–08:35 Abstract Sun Oct 25 08:30–08:35 4244RO - NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial Biomarkers & precision oncology Abstract Sun Oct 25 09:19–09:24 Talk Sun Oct 25 10:45–11:00 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Allele specific characteristics of KRASQ61 mutated gastrointestinal malignancies with clinical outcomes and transcriptomic features in pancreatic cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Chromosomal instability is associated with worse survival and an immunosuppressive tumor microenvironment in microsatellite stable colorectal cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Organ-specific response to KRAS inhibitors in metastatic colorectal cancer Gastrointestinal cancers Poster Sun Oct 25 12:00–12:45 Overall survival in young- vs average-onset metastatic colorectal cancer across actionable molecular subgroups: A 4,717-patient hierarchical analysis at MD Anderson Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:10–13:25 Emerging evidence in BRAFV600E-mutant mCRC Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 15:15–15:25 Talk Sun Oct 25 15:30–15:50 Pathological response for the win Melanoma & skin cancers Abstract Sun Oct 25 16:30–16:42 LBA5 - Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC Lung & thoracic cancersGastrointestinal cancers Chair Sun Oct 25 16:30–18:00 Rapid oral: Supportive and palliative care Nursing & supportive care Abstract Sun Oct 25 16:45–16:55 Invited Discussant 3469RO, 3085RO and 3895RO Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Proffered paper: Supportive and palliative care Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Talk Mon Oct 26 09:15–09:30 Abstract Mon Oct 26 09:24–09:36 Talk Mon Oct 26 10:35–10:55 Biology and mechanisms of action of novel immunotherapies Lung & thoracic cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 AXL protein expression by immunohistochemistry in sarcoma subtypes: Implications for antibody-drug conjugate development Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Clinical prediction model for early mortality in leukemia patients following inpatient chemotherapy Haematological malignancies Poster Mon Oct 26 12:00–12:45 Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLC Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Neoadjuvant and adjuvant tiragolumab plus atezolizumab in PD-L1-positive oral cavity squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Satellite Mon Oct 26 13:05–13:25 Charting the Path Forward in KRAS G12C Lung Cancer Lung & thoracic cancers Talk Mon Oct 26 14:45–15:00 Chair Mon Oct 26 14:45–16:15 Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 15:39–15:44 Abstract Mon Oct 26 15:44–15:56 Talk Mon Oct 26 16:30–16:45 IO-based systemic therapy (incl pt selection) Sarcoma, CNS, head & neck and rare cancers Satellite Mon Oct 26 19:25–19:50 Managing Complexity: Sequencing HER2-Directed Therapies After Progression Lung & thoracic cancersBiomarkers & precision oncology |
Institut Curie Paris, France | |
Private non-profit cancer centre in Paris, France, combining a research centre with hospital sites. | Booth Exhibiting at Booth 8042 Satellite Fri Oct 23 09:50–10:15 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Clinical utility of HPV circulating tumor DNA in anal cancer: Real-world data from a French high-volume center Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 HER2 IHC expression across multiple solid tumor types: Insights from the ESPERANZA Programme Biomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 SWI/SNF-deficient tumors define a distinct subset of cancers of unknown primary: Data from the French National CUP cohort Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Tebentafusp discontinuation after sustained disease control in metastatic uveal melanoma (mUM): A single-center ambispective observational study Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Tumor-bound factor H controls complement activation and is a potential therapeutic target in oral cavity and HPV-negative oropharyngeal squamous cell carcinoma Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 ctDNA and survival outcomes in first-line ICI-treated metastatic NSCLC-interim analysis Lung & thoracic cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 An in-depth multistate analysis of a national multidisciplinary tumour board (MTB) for patients with cancer of unknown primary Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Comprehensive genomic profiling in lacrimal duct carcinoma reveals HER2-driven biology and emerging therapeutic targets Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Integrated clinical and transcriptomic biomarkers predict survival and immune checkpoint inhibitor response in cancers of unknown primary Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 MTAP loss and HPV status in head and neck squamous cell carcinoma (HNSCC): A genomic landscape study Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:15–19:45 Satellite Fri Oct 23 18:15–18:20 Welcome Melanoma & skin cancers Satellite Fri Oct 23 19:15–19:40 Interactive Case and Panel Discussion: Applying Evidence to Practice Melanoma & skin cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Darovasertib with crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma (OptimUM-02): A subgroup analysis Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 PLUME: Overall survival results from a phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM) Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:05–13:35 Maximizing 1L outcomes in HR+ mBC Breast cancer Talk Sat Oct 24 17:00–17:15 How to monitor biomarkers and ctDNA Breast cancerBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Satellite Sun Oct 25 13:20–14:05 Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate Lung & thoracic cancers Satellite Sun Oct 25 14:05–14:25 Looking To the Future: How Emerging Strategies Could Address Unmet Needs in NSCLC Lung & thoracic cancers Talk Sun Oct 25 15:25–15:45 Toxicities of cytokines and intratumoral immunotherapies Nursing & supportive care Chair Sun Oct 25 18:30–20:00 Talk Sun Oct 25 19:25–19:45 Ongoing research and horizon scanning in cancer with ROS1 rearrangements Lung & thoracic cancers Talk Mon Oct 26 09:30–09:50 Poster Mon Oct 26 12:00–12:45 Epigenomic priming shapes chemoresistant tumor states in high-grade serous ovarian cancer Gynaecological cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 ctDNA for early detection of HPV-induced pelvic cancer relapse: A multicentric prospective study Gastrointestinal cancersGynaecological cancersBiomarkers & precision oncology |
City of Hope Duarte, CA | |
Independent cancer research and treatment organization based in Duarte, California, with an NCI-designated comprehensive cancer centre and sites across the US. | Booth Exhibiting at Booth 8038 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Genomic and phenotypic characterization of GPR65, HPK1, ENPP3 and CD70, novel targets of early phase therapeutics for metastatic renal cell carcinoma (mRCC) Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Abstract Sat Oct 24 08:30–08:40 Satellite Sat Oct 24 12:00–13:30 Satellite Sat Oct 24 12:00–12:10 Opening: Why Subcutaneous Immunotherapy Now? A Nurse Led Lens Nursing & supportive care Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 12:50–13:25 Nurse Panel session: How best to implement SC IO patient services in hospital and community settings Nursing & supportive care Satellite Sat Oct 24 13:25–13:30 Conclusion remarks Nursing & supportive care Satellite Sat Oct 24 18:43–19:23 Navigating the RCC treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 09:22–09:32 Talk Sun Oct 25 10:30–11:15 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 PARP inhibitors and platinum chemotherapy improve survival in pancreatic adenocarcinoma independent of HRD status Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Predictive response factors to CTLA4/PD-1 combinations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) Gastrointestinal cancersBiomarkers & precision oncology Talk Sun Oct 25 15:00–15:15 Talk Sun Oct 25 15:55–16:00 Poster Mon Oct 26 12:00–12:45 Talk Mon Oct 26 16:05–16:10 |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
European Organisation for Research and Treatment of Cancer (EORTC) Brussels, Belgium | |
Independent non-profit that runs international academic cancer clinical trials across Europe. | Booth Exhibiting at Booth S1041 Poster Fri Oct 23 13:00–15:00 Coverage of treatment-related toxicities by EORTC QLQ-C30 and QLQ-H&N43 in head and neck cancer Sarcoma, CNS, head & neck and rare cancersNursing & supportive care Poster Fri Oct 23 13:00–15:00 Diagnosis, treatment and follow-up practices for locally advanced nasopharyngeal cancer (NPC) in non-endemic regions: An EORTC led survey Sarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Abstract Sat Oct 24 15:47–15:52 |
Global contract research and healthcare data company providing clinical trial services and real-world evidence. | Booth Exhibiting at Booth 1001 Poster Fri Oct 23 13:00–15:00 Optimizing first-line treatment in R/M head and neck cancer: Systematic review of prognostic, predictive, and effect modifying factors Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 THRIVE-20-PF Spanish validation and a stepwise framework for psychometric evaluation and benchmarking in oncology Gastrointestinal cancersNursing & supportive care Satellite Sun Oct 25 19:45–19:55 How Do Patient-Reported Outcomes Influence Reimbursement Decisions? Nursing & supportive care |
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib. | Booth Exhibiting at Booth 1023 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 13:00–14:30 GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care Gynaecological cancers Talk Mon Oct 26 11:05–11:30 Poster Mon Oct 26 12:00–12:45 |
South Korean biotech developing bacteriophage and endolysin-based medicines, including phage-derived candidates for colorectal cancer. | Booth Exhibiting at Booth 1102 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
Clinical laboratory company offering diagnostic testing, including oncology tests, and central-laboratory services for drug development. | Booth Exhibiting at Booth 1088 Poster Mon Oct 26 12:00–12:45 Histotype, mutational, and immune gene expression correlates of PD-L1 immunohistochemistry in real-world cohort of ovarian cancer cases Gynaecological cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Validation of a multiparametric flow cytometry panel for quantifying CD20 expression in CLL whole blood during mosunetuzumab therapy Haematological malignanciesBiomarkers & precision oncology |
Finnish pharmaceutical company that co-developed the prostate cancer drug darolutamide with Bayer. | Booth Exhibiting at Booth 1047 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 |
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab. | Booth Exhibiting at Booth 1029 · Johnson & Johnson Innovative Medicine Poster Fri Oct 23 13:00–15:00 Identifying and assessing fit-for-use real-world data sources for homologous recombination repair mutations in prostate cancer: A systematic literature review supplemented by artificial intelligence Genitourinary cancersBiomarkers & precision oncology Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 14:00–15:30 J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers |
WebMD's medical news and continuing-education service for physicians and other clinicians. | Booth Exhibiting at Booth 8072 Satellite Fri Oct 23 09:45–11:15 Poster Fri Oct 23 13:00–15:00 Satellite Sat Oct 24 18:30–20:00 Satellite Sun Oct 25 13:00–14:30 |
Abbott Abbott Park, IL | |
Global healthcare company making diagnostics, medical devices and nutrition products; now owns Exact Sciences' cancer testing business. | Booth Exhibiting at Booth 8071 · Exact Sciences Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Satellite Mon Oct 26 13:00–14:30 |
Chinese precision oncology company offering cancer genomic profiling and early detection tests. | Booth Exhibiting at Booth 8029 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Analytical validation of onco-transcan for whole-transcriptome RNA expression profiling and PAM50 subtyping in solid tumors Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Clinical utility of FusionCapture RNA NGS for resolving ALK fusion variants to inform targeted therapy in lung cancer Lung & thoracic cancersBiomarkers & precision oncology |
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies. | Booth Exhibiting at Booth 8063 · Gilead and Kite Oncology Poster Fri Oct 23 13:00–15:00 Extending RWD–based external control arms from hematologic to lung malignancies for clinical and regulatory decision-making Haematological malignanciesLung & thoracic cancers Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers |
German science and technology company whose healthcare business markets oncology medicines including avelumab, cetuximab and tepotinib. | Booth Exhibiting at Booth 1034 Poster Fri Oct 23 13:00–15:00 Satellite Sat Oct 24 13:00–14:30 Merck Healthcare KGaA - Striving for more: The cutting edge of therapeutic developments in mCRC Gastrointestinal cancers Satellite Mon Oct 26 13:00–14:30 Merck Healthcare KGaA - CARE FOR RARE: Desmoid Tumours in Clinical Practice − Shifting Strategies & Evolving Perspectives Sarcoma, CNS, head & neck and rare cancers |
Swiss pharmaceutical company whose oncology medicines include ribociclib for breast cancer and radioligand therapies. | Booth Exhibiting at Booth 1059 Poster Fri Oct 23 13:00–15:00 Renal safety monitoring in oncology radioligand therapy trials Nursing & supportive care Satellite Sat Oct 24 13:00–14:30 Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Satellite Mon Oct 26 13:00–14:30 |
AbbVie North Chicago, IL | |
Global biopharmaceutical company with oncology medicines including venetoclax, ibrutinib and antibody-drug conjugates. | Booth Exhibiting at Booth 8034 Satellite Fri Oct 23 09:45–11:15 AbbVie - Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer Gynaecological cancers Poster Fri Oct 23 13:00–15:00 |
Elsevier Amsterdam, Netherlands | |
Scientific and medical publisher of journals including The Lancet and Cell, plus clinical information tools. | Booth Exhibiting at Booth P8091 Talk Mon Oct 26 08:30–08:35 Editorial triage and workshop objectives Nursing & supportive care Talk Mon Oct 26 09:13–09:23 Responsible AI in scientific publishing Nursing & supportive care |
German Breast Group (GBG) Neu-Isenburg, Germany | |
German academic research organisation that designs and runs clinical trials in breast cancer. | Booth Exhibiting at Booth 1095 Chair Sun Oct 25 10:15–11:45 Optimising treatment for HER2+ early breast cancer Breast cancer Talk Sun Oct 25 11:15–11:35 What to do after optimal neoadjuvant therapy? Breast cancer |
Spanish biopharmaceutical company developing and marketing marine-derived cancer medicines, including trabectedin and lurbinectedin. | Booth Exhibiting at Booth 1066 Poster Fri Oct 23 13:00–15:00 Satellite Sat Oct 24 18:30–20:00 PharmaMar - More time for patients: Reframing the course of ES-SCLC Lung & thoracic cancers |
Amoy Diagnostics (AmoyDx) Xiamen, China | |
Chinese maker of PCR and NGS companion diagnostic kits for cancer gene alterations. | Booth Exhibiting at Booth 8059 Poster Fri Oct 23 13:00–15:00 |
BioNTech Mainz, Germany | |
German biotech developing mRNA cancer immunotherapies, antibody-drug conjugates and bispecific antibodies. | Booth Exhibiting at Booth 8070 Poster Fri Oct 23 15:15–16:00 |
French digital platform for remote monitoring of cancer patients' symptoms between visits. | Booth Exhibiting at Booth 1086 Talk Mon Oct 26 11:05–11:15 |
Indian molecular diagnostics company making PCR and NGS test kits and instruments. | Booth Exhibiting at Booth 1060 Poster Fri Oct 23 13:00–15:00 Standardized CML detection and MRD monitoring using a lyophilized cold chain–free BCR-ABL RT-PCR assay on OnePCR and Rapi-Q platforms Haematological malignanciesBiomarkers & precision oncology |
Global contract research organization headquartered in Ireland, providing clinical development and trial services. | Booth Exhibiting at Booth 8005 Poster Fri Oct 23 13:00–15:00 Automated RECIST 1.1 quality assessment in oncology trials: A proof-of-concept framework for discrepancy detection and anomaly scoring Lung & thoracic cancersMelanoma & skin cancers |
US biotech developing targeted cancer therapies, including antibody-drug conjugates and a gamma secretase inhibitor for desmoid tumours. | Booth Exhibiting at Booth 8017 Poster Mon Oct 26 12:00–12:45 Exposure-response (ER) analyses to support the recommended dose of varegacestat (VAR) for patients (pts) with desmoid tumors (DT) Sarcoma, CNS, head & neck and rare cancers |
Genetic testing company whose Signatera tumour-informed ctDNA test tracks molecular residual disease and treatment response. | Booth Exhibiting at Booth 1015 Poster Fri Oct 23 15:15–16:00 Plasma whole-exome sequencing (pWES) reveals somatic landscape and clonal dynamics in metastatic urothelial carcinoma Genitourinary cancersBiomarkers & precision oncology |
NA | |
AI company building research agents and a biomedical knowledge base for drug development teams. | Booth Exhibiting at Booth 1090 |
Oncology company whose Tumor Treating Fields devices use electric fields to disrupt cancer cell division, used in glioblastoma, mesothelioma and lung cancer. | Booth Exhibiting at Booth 8032 Poster Fri Oct 23 13:00–15:00 |
Find buyers from ESMO 2026 exhibitors
Tell us what you sell and we’ll find the people at these exhibitors most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
- Exhibitors 235
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction